Recent advances in research and care of familial hypercholesterolaemia Heterozygous familial hypercholesterolaemia is a common, autosomal semi-dominant condition characterised by elevation of LDL cholesterol from birth and early onset of atherosclerotic cardiovascular di...

Despite advances, #familial #hypercholesterolaemia is still inadequately diagnosed and undertreated, with many affected people remaining at high risk of early #cardiovascular disease www.thelancet.com/journals/lan...
#HeFH #HoFH #ASCVD

#MedSky #EndoSKY #CardioSky

Recent advances in research and care of familial hypercholesterolaemia Heterozygous familial hypercholesterolaemia is a common, autosomal semi-dominant condition characterised by elevation of LDL cholesterol from birth and early onset of atherosclerotic cardiovascular di...

With major advances in knowledge about the disease, #familial #hypercholesterolaemia has become an exemplar for the practice of precision and personalised medicine thelancet.com/journals/lan...
#HoFH #HeFH #ASCVD

#MedSky #EndoSky #CardioSky

Inclisiran for children: is it worth it? Familial hypercholesterolaemia is one of the most common inherited metabolic disorders, with heterozygous familial hypercholesterolaemia (HeFH) affecting more than 30 million individuals worldwide, a ...

Lluís Masana & Daiana Ibarretxe comment on:
Inclisiran for children: is it worth it? thelancet.com/journals/lan...
#heterozygous #familial #hypercholesterolaemia #HeFH #ASCVD

#MedSky #EndoSky #CardioSky

The application of implementation science to expanding knowledge of #familial #hypercholesterolaemia has enabled the development and design of potentially more effective models of care thelancet.com/journals/lan...
#HoFH #HeFH #ASCVD

#MedSky #EndoSky #CardioSky

Does siRNA therapy against ANGPTL3 bring new hope in homozygous familial hypercholesterolaemia? Homozygous familial hypercholesterolaemia is a rare and devastating autosomal co-dominant disorder affecting between one in 160 000 and 300 000 people in the general population.1 Homozygous familial h...

Linked Comment by Raul D Santos:
Does siRNA therapy against ANGPTL3 bring new hope in #homozygous #familial #hypercholesterolaemia? www.thelancet.com/journals/lan...
#zodasiran #HoFH #LDL #cholesterol

#MedSky #EndoSky #CardioSky

Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial Quarterly dosed zodasiran shows evidence of reductions in LDL cholesterol with a favourable safety profile, in patients with HoFH receiving background lipid-lowering therapy. Further investigation in ...

Quarterly dosed #zodasiran shows evidence of reductions in #LDL #cholesterol with a favourable safety profile, in patients with #HoFH receiving background lipid-lowering therapy www.thelancet.com/journals/lan...
#homozygous #familial #hypercholesterolaemia

#MedSky #EndoSky #CardioSky

Does siRNA therapy against ANGPTL3 bring new hope in homozygous familial hypercholesterolaemia? Homozygous familial hypercholesterolaemia is a rare and devastating autosomal co-dominant disorder affecting between one in 160 000 and 300 000 people in the general population.1 Homozygous familial h...

Linked Comment by Raul D Santos:
Does siRNA therapy against ANGPTL3 bring new hope in #homozygous #familial #hypercholesterolaemia? thelancet.com/journals/lan...
#HoFH

#MedSky #EndoSky #CardioSky

New—Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with #homozygous #familial #hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial thelancet.com/journals/lan...
#HoFH

#MedSky #EndoSky #CardioSky

Although heterozygous #familial #hypercholesterolaemia represents one of the most common monogenic conditions in the general population, homozygous familial hypercholesterolaemia is much rarer, occurring in between one in 160 000 & one in 450 000 individuals www.thelancet.com/journals/lan...
#ASCVD

Despite advances, #familial #hypercholesterolaemia remains an underdiagnosed and untreated condition, with an urgent need for the design and implementation of effective models of care www.thelancet.com/journals/lan...
#ASCVD #HeFH #HoFH

#MedSky #EndoSky #CardioSky

The application of implementation science to expanding knowledge of #familial #hypercholesterolaemia has enabled the development and design of potentially more effective models of care www.thelancet.com/journals/lan...
#ASCVD #cholesterol

#MedSky #EndoSky #CardioSky

Recent advances in research and care of familial hypercholesterolaemia Heterozygous familial hypercholesterolaemia is a common, autosomal semi-dominant condition characterised by elevation of LDL cholesterol from birth and early onset of atherosclerotic cardiovascular di...

Although #heterozygous #familial #hypercholesterolaemia was traditionally thought to affect approximately one in 500 individuals in the general population, multiple contemporary epidemiological studies have revealed that this condition is much more common www.thelancet.com/journals/lan...
#ASCVD

Recent advances in research and care of familial hypercholesterolaemia Heterozygous familial hypercholesterolaemia is a common, autosomal semi-dominant condition characterised by elevation of LDL cholesterol from birth and early onset of atherosclerotic cardiovascular di...

Heterozygous familial #hypercholesterolaemia is a common, autosomal semi-dominant condition characterised by elevation of #LDL #cholesterol from birth and early onset of #atherosclerotic #cardiovascular disease www.thelancet.com/journals/lan...
#HeFH #ASCVD

#MedSky #EndoSky #CardioSky

A Multisystemic Presentation of Familial Hypercholesterolaemia: A Case Report - Premier Science Xanthelasma palpebrarum, Heterozygous familial Hypercholesterolemia, ldlr gene mutation, Tuberous and eruptive xanthomas, pcsk9 inhibitor

doi.org/10.70389/PJC...

#multisystemic #familial #hypercholesterolaemia

Familial hypercholesterolaemia is still inadequately diagnosed and undertreated, with many affected people remaining at high risk of early cardiovascular disease www.thelancet.com/journals/lan...
#familial #hypercholesterolaemia #ASCVD

#MedSky #EndoSky #CardioSky

Recent advances in research and care of familial hypercholesterolaemia Heterozygous familial hypercholesterolaemia is a common, autosomal semi-dominant condition characterised by elevation of LDL cholesterol from birth and early onset of atherosclerotic cardiovascular di...

New—Recent advances in research and care of familial hypercholesterolaemia thelancet.com/journals/lan...
#familial #hypercholesterolaemia #ASCVD

#MedSky #EndoSky #CardioSky

Genetic Determinants of the Familial Hypercholesterolaemia Phenotype Individuals with familial hypercholesterolaemia (FH) have severely elevated plasma concentrations of low-density lipoprotein cholesterol (LDL-C) from birth and as a consequence have an elevated morbi...

New early view article from invited world renowned expert Prof. Steve Humphries!

In this review, he explores the genetic determinants of the familial #hypercholesterolaemia (FH) phenotype.

A must-read for anyone in cardiovascular genetics.

🔗Read: onlinelibrary.wiley.com/doi/10.1111/...

Genetic Determinants of the Familial Hypercholesterolaemia Phenotype Individuals with familial hypercholesterolaemia (FH) have severely elevated plasma concentrations of low-density lipoprotein cholesterol (LDL-C) from birth and as a consequence have an elevated morbi....

An Early View: A review elucidating the #genetic architecture of familial #hypercholesterolaemia (FH) phenotype and the future of identifying novel genetic variants that cause FH.

onlinelibrary.wiley.com/doi/10.1111/...

The March Issue of @TheLancetEndo is now online, featuring #thyroid cancer in the USA, homozygous familial #hypercholesterolaemia, #obesity, #heart failure, type 2 #diabetes, automated #insulin delivery, #T1D screening, #prediabetes, #CGM, #Mpox, and more bit.ly/2LArJXX
#MedSky #EndoSky

Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial The LDL cholesterol response was highly variable, but generally similar in patients treated with both lerodalcibep and evolocumab. Importantly, the study showed the inability to predict response based...

Lerodalcibep and evolocumab for the treatment of #homozygous #familial #hypercholesterolaemia with #PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial www.thelancet.com/journals/lan...
#HoFH #LDL #cholesterol